Verano Holdings (VRNO) Change in Accured Expenses (2021 - 2026)
Verano Holdings (VRNO) reported Change in Accured Expenses of -$15.7 million for Q1 2026, down 74.1% year-over-year from -$60.7 million in Q1 2025, and down 489.04% quarter-over-quarter from $4.0 million in Q4 2025.
Verano Holdings (VRNO) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Change in Accured Expenses data on file, last reported at -$15.7 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$15.7 million, down 74.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.2 million (up 31.07% YoY), and the FY2025 annual result was -$5.5 million, up 67.69% from the prior year.
- Change in Accured Expenses fell to -$15.7 million in Q1 2026 per VRNO's latest filing, from $4.0 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $32.2 million in Q4 2022 and troughed at -$18.0 million in Q3 2022.
- A 5-year average of -$1.5 million and a median of -$5.2 million in 2023 frame the typical range for Change in Accured Expenses.
- On a YoY basis, Change in Accured Expenses climbed as much as 203.91% in 2022 and fell as far as 1092.79% in 2022.
- A 5-year view of Change in Accured Expenses shows it stood at $32.2 million in 2022, then decreased by 19.29% to $26.0 million in 2023, then sank by 139.64% to -$10.3 million in 2024, then soared by 139.21% to $4.0 million in 2025, then tumbled by 489.04% to -$15.7 million in 2026.
- Business Quant data shows VRNO's Change in Accured Expenses at -$15.7 million in Q1 2026, $4.0 million in Q4 2025, and -$1.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 10.02 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 23.00 Mn |
| 10 | Verano Holdings | - | - | 98.98 Mn | -15.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.72 Mn |
| Mar 31, 2026 | -15.72 Mn |
| Dec 31, 2025 | 4.04 Mn |
| Dec 31, 2025 | 4.04 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Jun 30, 2025 | 939,000.00 |
| Jun 30, 2025 | 939,000.00 |
| Mar 31, 2025 | -9.03 Mn |
| Mar 31, 2025 | -9.03 Mn |
| Dec 31, 2024 | -10.31 Mn |
| Dec 31, 2024 | -10.31 Mn |
| Sep 30, 2024 | -1.61 Mn |
| Sep 30, 2024 | -1.61 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Mar 31, 2024 | -8.33 Mn |
| Mar 31, 2024 | -8.33 Mn |
| Dec 31, 2023 | 26.00 Mn |
| Dec 31, 2023 | 26.00 Mn |